Monograph Details
|
|
Urogenital System
> Benign prostatic hyperplasia/urinary retention
|
|
FLOMAX |
| Manufacturer |
|
Boehringer Ingelheim Pharmaceuticals |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
α1A -blocker. |
| Generic Name |
|
Tamsulosin HCl 0.4mg; caps. |
| Indications |
|
BPH. |
| Children |
|
Not applicable. |
| Adults |
|
Swallow whole. Take ½ hr after same meal of each day. Initially 0.4mg once daily; may increase to 0.8mg once daily after 2–4 weeks if response is inadequate. If therapy is interrupted, resume at 0.4mg once daily and retitrate. |
| Precautions |
|
Rule out prostate cancer. Sulfa allergy. Syncope. End-stage renal disease. Cataract surgery (intraoperative floppy iris syndrome possible). |
| Interactions |
|
Do not use with other α-blockers. Caution with cimetidine (esp. with tamsulosin >0.4mg/day), warfarin. |
| Adverse Reactions |
|
Abnormal ejaculation, postural hypotension, dizziness, rhinitis, cough, somnolence, sinusitis, amblyopia, decreased libido, insomnia, syncope; rare: priapism. |
| How Supplied |
|
Caps—100 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
